Weitao Biotechnology

Weitao Biotechnology (also known as Vivacta Bio) is a Shanghai-based biotechnology company specializing in the development of next-generation in vivo CAR-T cell therapies for oncology and autoimmune diseases. Spun off from Grit Biotherapeutics (Grit Bio) in 2025, the company leverages a proprietary T-cell-targeted lipid nanoparticle (T-LNP) platform to deliver mRNA encoding chimeric antigen receptors directly into patient T cells in vivo. This approach bypasses the complex, costly, and time-consuming ex vivo manufacturing and lymphodepleting chemotherapy associated with traditional CAR-T therapies. Its lead candidate, GT801, is an anti-CD19 in vivo CAR-T therapy currently in Phase 1 clinical development, which has demonstrated promising safety and efficacy in patients with B-cell malignancies and autoimmune hemolytic anemia (AIHA).